Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front Med Chin    2010, Vol. 4 Issue (3) : 308-316     DOI: 10.1007/s11684-010-0103-9
Early diagnosis and therapeutic choice of Klebsiella pneumoniae liver abscess
Jing LI, Ying FU, Ji-Yao WANG, Chuan-Tao TU, Xi-Zhong SHEN, Lei LI, Wei JIANG()
Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Download: PDF(217 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Nowadays, pyogenic liver abscess (PLA) is still a common and severe intra-abdominal infection, and Klebsiella pneumoniae had emerged as the most common pathogenic bacteria worldwide in the past ten years. Our study aims to achieve an early pathogenic diagnosis and rational therapy modality for Klebsiella pneumoniae liver abscess (KLA) through clinical data analysis. A total of 197 inpatients in Zhongshan Hospital, Shanghai, diagnosed as having liver abscess between March 2001 and September 2009 were enrolled. Patients with monomicrobial infection were divided into two groups: patients with K. pneumoniae liver abscess (KLA group, n=106) and those with non-Klebsiella pneumoniae liver abscess (NKLA group, n=56). A retrospective analysis was made between these two groups on the aspects of underlying diseases, clinical characteristics, laboratory data, culture results, and imaging findings. To evaluate the effects of different medical interventions, monomicrobial KLA patients were further divided into four subgroups (percutaneous liver aspiration, aspiration plus antibiotics flushing, aspiration plus retained catheter, and aspiration plus antibiotics flushing and retained catheter), and corresponding therapeutic effects were analyzed. KLA was more likely to occur in patients with coexisting diseases such as diabetes mellitus (53.77% vs 25.00%, P=0.001) and hepatic adipose infiltration (16.04% vs 5.36%, P=0.029). Compared to NKLA group, clinical characteristics including abdominal pain (40.57% vs 57.14%, P=0.044), hypodynamia (19.81% vs 46.43%, P=0.001), and hepatomegaly (4.72% vs 14.29%, P=0.033) were much milder, but with a higher fasting blood glucose level (7.84?±?0.36 vs 5.76?±?0.30, P=0.001) on admission in KLA group. In addition, KLA abscess often appeared singly in the right lobe of the liver with gas forming nature (32.88% vs 13.51%, P=0.039), unsmooth rim (71.23% vs 40.54%, P=0.002), and dynamic septum enhancement (41.10% vs 16.22%, P=0.009). Compared to mono aspiration subgroup, additional antibiotic flushing could not further improve clinical outcomes of KLA patients (P>0.05); however, the retained catheter showed obvious advantage in reducing abscess diameter (34.38?±?3.25 mm vs 22.67?±?2.37 mm, P=0.017). It can be concluded that the strong association with diabetes, milder clinical symptoms, and gas-forming nature in CT images makes early pathogenic diagnosis of KLA possible. Comparatively, ultrasonography-guided percutaneous liver aspiration with retained catheter may be the most rational intervention modality of KLA.

Keywords liver abscess      Klebsiella pneumoniae      computed tomography      therapy     
Corresponding Authors: JIANG Wei,   
Issue Date: 05 September 2010
URL:     OR
culture results of 197 enrolled patientsnumber of cases
Klebsiella pneumoniae116
Escherichia coli27
Pseudomonas aeruginosa13
Staphylococcus aureus5
Citrobacter freumdii4
Enterobacter cloacae3
coagulase negative staphylococcus2
Staphylococcus epidermidis2
Morganella morganii2
short wave unit cell bacteria1
Tab.1  Microbiological data of pyogenic liver abscess patients
underlying diseasesKLA (n=106)NKLA (n=56)P value
diabetes mellitus57 (53.8%)14 (25.0%)<0.001a
biliary diseases24 (22.6%)17 (30.4%)NSa
abdominal surgeries18 (17.0%)30 (35.4%)<0.001a
liver cirrhosis3 (2.8%)1 (1.8%)NSb
chronic hepatitis B4 (3.8%)5 (8.9%)NSb
malignant tumors3 (2.8%)7 (12.5%)<0.05a
hepatic adipose infiltration17 (16.0%)3 (5.4%)<0.05a
chemo-radiotherapies2 (1.9%)6 (10.7%)<0.05a
diabetes+ biliary diseases11 (10.4%)2 (3.6%)NSa
Tab.2  Underlying diseases of . liver abscess patients
clinical parametersKLA (n=106)NKLA (n=56)P value
chill78 (73.58%)38 (67.86%)NSa
abdominal pain43 (40.57%)32 (57.14%)<0.05a
vomiting26 (24.53%)12 (21.43%)NSa
anorexia53 (50.00%)30 (53.57%)NSa
fatigue21 (19.81%)26 (46.43%)0.001a
highest body temperature/°C39.41±0.0939.10±0.13NSa
hepatic percussion pain41 (38.68%)27 (48.21%)NSa
liver tenderness31 (29.25%)21 (37.50%)NSa
hepatomegaly5 (4.72%)8 (14.29%)<0.05a
leucocyte count (×109/L)13.30±0.5912.73±1.07NSc
percentage of neutrophils /%80.64±1.1479.33±1.46NSc
blood glucose/mmol·L-17.84±0.365.76±0.300.001c
Tab.3  Clinical characteristics and laboratory parameters of KLA patients
ultrasonography findingsKLA (n=106)NKLA (n=56)P value
solitary (n=1)60 (82.19%)30 (81.08%)NSa
multiple (n>1)13 (17.81%)7 (18.92%)NSa
left lobe11 (15.07%)5 (16.67%)NSa
right lobe47 (64.38%)24 (64.87%)NSa
junction of left and right lobe2 (2.74%)1 (2.74%)NSb
diameter of abscess/mm73.85±2.4073.77±3.22NSc
gas-formation in abscess27 (25.47%)6 (10.71%)<0.001a
abscess with compartments41 (38.67%)20 (35.71%)NSa
CT findingsKLA (n=73)NKLA (n=37)P value
plain scan
abscess with clear edge21 (28.77%)22 (59.46%)NSa
abscess with blurring edge52 (71.23%)15 (40.54%)<0.05a
gas-formation in abscess24 (32.88%)5 (13.51%)<0.05a
biliary pneumatosis7 (9.59%)3 (8.11%)NSa
pleural effussion25 (34.25%)11 (29.73%)NSa
hepatic arterial phase
no enhancement0 (0)0 (0)NSb
septal enhancement30 (41.10%)6 (16.22%)<0.05a
abnormal perfusion5 (6.85%)2 (5.41%)NSb
portal venous phase
no enhancement0 (0)2 (5.4%)NSb
peripheral enhancement28 (38.36%)12 (32.4%)NSa
non-peripheral enhancement2 (2.74%)2 (5.4%)NSb
Tab.4  Imaging findings of liver abscess in KLA patients
treatment responsesgroup I (n=24)group II (n=52)group III (n=23)
decline in percentage of neutrophils/%17.72±2.4116.21±1.5915.20±2.18
reduction of abscess diameter/mm22.67±2.3724.45±3.1734.38±3.25 *#
time to defervescence/day5.79±1.245.35±0.845.18±1.57
Tab.5  Treatment responses to different aspiration modalities of liver abscess patients
Fig.1  Typical abdominal CT images of a 77-year-old female KLA patient. (a) Plain scan: the abscess is the low-density lesion with blurring edge in the right lobe of the liver. Red arrow indicates gas cavities of the abscess, which are at a relatively-upper location within the abscess. (b)-(d) Hepatic arterial phase: during enhanced period, the margin of lesion still cannot be clearly shown. Red arrow indicates the gas cavities; blue arrow indicates the imaging signs of septal enhancement and disarranged internal structure of the abscess; yellow arrow indicates little flocculent shadow in the hepatorenal recess with its unclear boundaries to the upper pole of the right kidney. (e)-(f) Hepatic parenchymal phase: during hepatic parenchymal phase, delayed and weakened enhancement of the abscess is shown in CT images. Its margin is unclear with still visible gas cavities indicated by red arrow. KLA: liver abscess.
Fig.2  Comparison of abdominal CT images between KLA and NKLA. (a) CT images of a 57-year-old male KLA patient with concomitant diabetes: circular shadow of low and uneven density can be seen in the caudate lobe near the second hepatic portal. With a diameter of 90 mm, a shadow of much lower density and gas cavities can be seen in the center of the abscess. During enhanced scanning, the margin and internal septations of abscess shows a honeycomb-like structure. Intrahepatic bile ducts show slight dilation. (b) CT images of a 51-year-old female patient with liver abscess: irregular low-density lesion with a honeycomb-like structure can be seen in the right lobe of the liver. Obvious cystic wall enhancement can be seen during enhanced scanning. There is no stenosis or filling defect of hepatic vessels. (c) CT images of a 65-year-old female patient with liver abscess: patchy shadow of low-and-even density and clear edge can be seen in the right lobe of the liver. By enhanced CT scan, the peripheral enhancement is more dramatic than non-peripheral enhancement. Septation is visible inside the abscess and hepatic blood vessels are evenly distributed. KLA: liver abscess; NKLA: non- liver abscess.
1 Cheung N K, Malfitan R C, Najem A Z, Rush B F Jr. Pyogenic liver abscess. Am Surg , 1978, 44(5): 272–278
2 Rahimian J, Wilson T, Oram V, Holzman R S. Pyogenic liver abscess: recent trends in etiology and mortality. Clin Infect Dis , 2004, 39(11): 1654–1659
doi: 10.1086/425616
3 Lee K T, Wong S R, Sheen P C. Pyogenic liver abscess: an audit of 10 years’ experience and analysis of risk factors. Dig Surg , 2001, 18(6): 459–465 , discussion 465-466
doi: 10.1159/000050194
4 Kim S B, Je B K, Lee K Y, Lee S H, Chung H H, Cha S H. Computed tomographic differences of pyogenic liver abscesses caused by Klebsiella pneumoniae and non-Klebsiella pneumoniae. J Comput Assist Tomogr , 2007, 31(1): 59–65
doi: 10.1097/01.rct.0000224629.48068.69
5 Lederman E R, Crum N F. Pyogenic liver abscess with a focus on Klebsiella pneumoniae as a primary pathogen: an emerging disease with unique clinical characteristics. Am J Gastroenterol , 2005, 100(2): 322–331
doi: 10.1111/j.1572-0241.2005.40310.x
6 Hui J Y, Yang M K, Cho D H, Li A, Loke T K, Chan J C, Woo P C. Pyogenic liver abscesses caused by Klebsiella pneumoniae: US appearance and aspiration findings. Radiology , 2007, 242(3): 769–776
doi: 10.1148/radiol.2423051344
7 Pastagia M, Arumugam V. Klebsiella pneumoniae liver abscesses in a public hospital in Queens, New York. Travel Med Infect Dis, 2008, 6(4): 228–233
doi: 10.1016/j.tmaid.2008.02.005
8 Pope J V, Teich D L, Clardy P, McGillicuddy D C. Klebsiella pneumoniae liver abscess: an emerging problem in North America. J Emerg Med , 2008, Nov6. [epub ahead of print]
9 Lee H L, Lee H C, Guo H R, Ko W C, Chen K W. Clinical significance and mechanism of gas formation of pyogenic liver abscess due to Klebsiella pneumoniae. J Clin Microbiol , 2004, 42(6): 2783–2785
doi: 10.1128/JCM.42.6.2783-2785.2004
10 Medeiros A A. Nosocomial outbreaks of multiresistant bacteria: extended-spectrum beta-lactamases have arrived in North America. Ann Intern Med , 1993, 119(5): 428–430
11 Chan K S, Yu W L, Tsai C L, Cheng K C, Hou C C, Lee M C, Tan C K. Pyogenic liver abscess caused by Klebsiella pneumoniae: analysis of the clinical characteristics and outcomes of 84 patients. Chin Med J (Engl) , 2007, 120(2): 136–139
12 Fallon R J. The relationship between the biotype of Klebsiella species and their pathogenicity. J Clin Pathol , 1973, 26(7): 523–528
doi: 10.1136/jcp.26.7.523
13 Kang C I, Kim S H, Bang J W, Kim H B, Kim N J, Kim E C, Oh M D, Choe K W. Community-acquired versus nosocomial Klebsiella pneumoniae bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance. J Korean Med Sci , 2006, 21(5): 816–822
doi: 10.3346/jkms.2006.21.5.816
14 Schiappa D A, Hayden M K, Matushek M G, Hashemi F N, Sullivan J, Smith K Y, Miyashiro D, Quinn J P, Weinstein R A, Trenholme G M. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis , 1996, 174(3): 529–536
15 Wiener J, Quinn J P, Bradford P A, Goering R V, Nathan C, Bush K, Weinstein R A. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA , 1999, 281(6): 517–523
16 Wong W M, Wong B C, Hui C K, Ng M, Lai K C, Tso W K, Lam S K, Lai C L. Pyogenic liver abscess: retrospective analysis of 80 cases over a 10-year period. J Gastroenterol Hepatol , 2002, 17(9): 1001–1007
doi: 10.1046/j.1440-1746.2002.02787.x
17 Elgindy N, Lindholm H, Gunvén P. High-dose percutaneous ethanol injection therapy of liver tumors. Patient acceptance and complications. Acta Radiol , 2000, 41(5): 458–463
18 Okano H, Shiraki K, Inoue H, Kawakita T, Yamamoto N, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Murata K, Nakano T. Clinicopathological analysis of liver abscess in Japan. Int J Mol Med , 2002, 10(5): 627–630
19 Yang C C, Yen C H, Ho M W, Wang J H. Comparison of pyogenic liver abscess caused by non-Klebsiella pneumoniae and Klebsiella pneumoniae. J Microbiol Immunol Infect , 2004, 37(3): 176–184
20 Lim S W, Lee E J, Lee S W, Kim S M, Kim J H, Kim B J, Jang B I, Kim T N, Chung M K. Clinical significance of Klebsiella pneumoniae in liver abscess. Korean J Gastroenterol , 2003, 42(3): 226–231
21 Moon W K, Im J G, Yeon K M, Han M C. Complications of Klebsiella pneumonia: CT evaluation. J Comput Assist Tomogr , 1995, 19(2): 176–181
doi: 10.1097/00004728-199503000-00002
[1] Aining Xu,Lin Cheng. Chemical transdifferentiation: closer to regenerative medicine[J]. Front. Med., 2016, 10(2): 152-165.
[2] Wei Lu,Qingzhang Zhou,Hao Yang,Hao Wang,Yexing Gu,Qi Shen,Jinglun Xue,Xiaoyan Dong,Jinzhong Chen. Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX[J]. Front. Med., 2016, 10(2): 212-218.
[3] Jiangnan Liu,Bin Yi,Zhe Zhang,Yi Cao. CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells and hepatocytes[J]. Front. Med., 2016, 10(2): 204-211.
[4] Zhi Xu,Chunxiang Cao,Haiyan Xia,Shujing Shi,Lingzhi Hong,Xiaowei Wei,Dongying Gu,Jianmin Bian,Zijun Liu,Wenbin Huang,Yixin Zhang,Song He,Nikki Pui-Yue Lee,Jinfei Chen. Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma[J]. Front. Med., 2016, 10(1): 52-60.
[5] Yi Cao. Environmental pollution and DNA methylation: carcinogenesis, clinical significance, and practical applications[J]. Front. Med., 2015, 9(3): 261-274.
[6] Peter B. Alexander,Xiao-Fan Wang. Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies[J]. Front. Med., 2015, 9(2): 134-138.
[7] Farhad Sahebjam,John M. Vierling. Autoimmune hepatitis[J]. Front. Med., 2015, 9(2): 187-219.
[8] Xiaolong Wei,Chunfa Chen,Didi Xi,Jinwen Bai,Wenhe Huang,Luoxiang Rong,Mingyao Wu,Guojun Zhang. A case of primary neuroendocrine breast carcinoma that responded to neo-adjuvant chemotherapy[J]. Front. Med., 2015, 9(1): 112-116.
[9] Yingchen Li,Guoheng Hu,Qilai Cheng. Implantation of human umbilical cord mesenchymal stem cells for ischemic stroke: perspectives and challenges[J]. Front. Med., 2015, 9(1): 20-29.
[10] Bao-Zhu Yuan,Junzhi Wang. The regulatory sciences for stem cell-based medicinal products[J]. Front. Med., 2014, 8(2): 190-200.
[11] James S. Park,Calvin Pan. Current recommendations of managing HBV infection in preconception or pregnancy[J]. Front. Med., 2014, 8(2): 158-165.
[12] Yunfeng Fu, Xinyu Wang, Zimin Pan, Xing Xie. Clinical outcomes and prognostic factors of patients with epithelial ovarian cancer subjected to first-line treatment: a retrospective study of 251 cases[J]. Front Med, 2014, 8(1): 91-95.
[13] Dan Xiao, Nanshan Zhong, Chunxue Bai, Qingyu Xiu, Canmao Xie, Dayi Hu, Yun Mao, Roland Perfekt, Elisabeth Kruse, Qing Li, John Jiangnan Liu, Chen Wang. Nicotine gum or patch treatment for smoking cessation and smoking reduction: a multi-centre study in Chinese physicians[J]. Front Med, 2014, 8(1): 84-90.
[14] Somanath Padhi, Renu G’ Boy Varghese, Anita Ramdas, Manjiri Dilip Phansalkar, RajLaxmi Sarangi. Hemophagocytic lymphohistiocytosis: critical reappraisal of a potentially under-recognized condition[J]. Front Med, 2013, 7(4): 492-498.
[15] Jing Liu, Jinbo Yue, Ligang Xing, Jinming Yu. Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer[J]. Front Med, 2013, 7(2): 172-179.
Full text